Association of Hyperadiponectinemia With Severity of Ventricular Dysfunction in Congestive Heart Failure

Nakamura, Toshio; Funayama, Hiroshi; Kubo, Norifumi; Yasu, Takanori; Kawakami, Masanobu; Saito, Muneyasu; Momomura, Shin‐ichi; Ishikawa, San‐e

doi:10.1253/circj.70.1557

Cited by 74 publications

(53 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, adiponectin levels are positively correlated with the levels of brain natriuretic peptide and the severity of ventricular dysfunction estimated according to the New York Heart Association (NYHA). 40,41 Moreover, it is suggested that adiponectin predisposes mortality and morbidity in patients with heart failure. 42 Considering the vasoprotective and cardioprotective properties of adiponectin, the results above are easily explained.…”

Section: Obesity and Adiponectinmentioning

confidence: 99%

Relationship between adiponectin, obesity and insulin resistance

Balsan¹,

Vieira²,

Oliveira³

et al. 2015

Rev. Assoc. Med. Bras.

148

100

View full text Add to dashboard Cite

Conflict of interest: noneObjectives: the conditions of obesity and overweight pose a major risk for a number of comorbidities, including clinical syndromes resulting from atherosclerotic disease. Recent studies strongly indicate that adipose tissue is an active endocrine organ that secretes bioactive factors such as adipokines. Adiponectin appears to have a regulatory role in the mechanism of insulin resistance and in the development of atherosclerosis. This systematic review aims to evaluate the anti-atherogenic effects of adiponectin and its properties to improve and mimic metabolic and vascular actions of insulin and its influence on endothelial function. Methods: a qualitative, exploratory and literature review was performed in the PubMed, Portal Capes and Scielo databases using as key-words "adiponectin", "obesity", "insulin resistance", "anti-inflammatory", "therapeutic strategies" and "future prospects". Results: evidence suggests that adiponectin has anti-atherogenic properties with anti-inflammatory effects on the vascular wall. Moreover, it modifies the vascular intracellular signaling and has indirect antioxidant effects on the human myocardium. On the other hand, there are studies suggesting that increased levels of adiponectin are paradoxically associated with a worse prognosis in heart failure syndrome, although the mechanisms are not clear. Conclusion: it is not clear whether adiponectin levels have any clinical significance for risk stratification in cardiovascular disease or if they simply reflect the activation of complex underlying mechanisms. Changes in lifestyle and some drug treatments for hypertension and coronary heart disease have shown significant effect to increase adiponectin levels, and simultaneously decrease in insulin resistance and endothelial dysfunction.

show abstract

Section: Obesity and Adiponectinmentioning

confidence: 99%

Relationship between adiponectin, obesity and insulin resistance

Balsan¹,

Vieira²,

Oliveira³

et al. 2015

Rev. Assoc. Med. Bras.

148

100

View full text Add to dashboard Cite

show abstract

“…High levels are associated with increased mortality and severity in patients with chronic HF, including dilated cardiomyopathy. [37][38][39][40][41] Patients with HF and cachexia have a striking increase in the plasma adiponectin level compared with those with HF and no cachexia. 42 Low BMI, which is associated with elevated adiponectin level, may be linked to increased mortality following the onset of HF.…”

Section: Heart Failure (Hf)mentioning

confidence: 99%

Adiponectin and Cardiovascular Disease

Shibata

Ouchi

Murohara

2009

Circ J

195

142

View full text Add to dashboard Cite

Obesity is strongly associated with metabolic and cardiovascular disorders. Adiponectin is an adipose-derived plasma protein that is downregulated in subjects with obesity-related disorders. Low levels of adiponectin are associated with the increased prevalence of obesity-linked cardiovascular diseases, including ischemic heart disease and peripheral artery disease. Experimental findings have shown that adiponectin has beneficial effects in the cardiovascular system by directly acting on the component cells of the heart and blood vessels. Adiponectin protects cardiovascular tissues under conditions of stress through a number of mechanisms: inhibition of pro-inflammatory and hypertrophic responses, and stimulation of endothelial cell responses. These effects of adiponectin are mainly attributed to the modulation of signaling molecules, including AMP-activated protein kinase. Thus, adiponectin could be a promising therapeutic target for cardiovascular diseases. (Circ J 2009; 73: 608 -614)

show abstract

“…20 Nevertheless, it remains uncertain whether adiponectin has prognostic potential in Asians, and the difference in the circulating adiponectin levels of Caucasian and Asian patients suggests that the prognostic potential of Circ J 2007; 71: 623 -630 (Received June 26, 2006; revised manuscript received January 29, 2007; accepted February 9, 2007 Background Congestive heart failure (CHF) is associated with altered energy homeostasis and myocardial inflammation, hypertrophy, and fibrosis. Adiponectin, an insulin-sensitizing adipocytokine, may affect these pathogenic factors, and the circulating adiponectin level may serve as a biological marker of CHF.…”

Section: Circulation Journal Vol71 May 2007mentioning

confidence: 99%

Serum Adiponectin Level as an Independent Predictor of Mortality in Patients With Congestive Heart Failure

Tamura

Furukawa

Taniguchi

et al. 2007

Circ J

View full text Add to dashboard Cite

espite recent improvements in survival, the 5-year mortality rate for patients with congestive heart failure (CHF) ranges between 40% and 60%. 1,2 The discovery of risk markers for CHF and their appropriate use have contributed to improved screening, prevention, diagnosis and treatment of CHF. Because the pathophysiology of CHF is complex, a variety of markers associated with different pathophysiologic conditions may be used in the management of CHF.Adiponectin is an insulin-sensitizing adipocytokine that regulates energy metabolism by increasing free fatty acid oxidation in skeletal myocytes and gluconeogenesis in the liver. [3][4][5] In addition to its beneficial effects on both lipid and glucose metabolism, adiponectin has antiinflammatory properties. 6 It reduces the endothelial expression of cell adhesion molecules and the monocyte/macrophage production of inflammatory cytokines; however, it induces antiinflammatory cytokines. 7-10 Moreover, in a mouse model of pressure overload adiponectin had antihypertrophic effects on cardiac myocytes, and its deficiency exacerbated CHF. 11,12 Myocardial expression of adiponectin receptor 1 and adiponectin receptor 2 suggest possible effects of Circulation Journal Vol.71, May 2007adiponectin on cardiac myocytes. 13,14 Adiponectin can also inhibit growth factor-mediated fibroblast proliferation and prevent fibrosis. 15 Because these factors, namely, myocardial inflammation, hypertrophy and fibrosis, and dysregulation of myocardial lipid/glucose metabolisms can either cause or exacerbate CHF, 16,17 adiponectin may play a protective role in CHF.Increased levels of circulating adiponectin and the prognostic potential of adiponectin have been reported in Caucasian CHF patients 18,19 and very recently, an increase in the circulating adiponectin level and an association of this with the severity of CHF have been shown in Japanese CHF patients. 20 Nevertheless, it remains uncertain whether adiponectin has prognostic potential in Asians, and the difference in the circulating adiponectin levels of Caucasian and Asian patients suggests that the prognostic potential of Circ J 2007; 71: 623 -630 (Received June 26, 2006; revised manuscript received January 29, 2007; accepted February 9, 2007 Background Congestive heart failure (CHF) is associated with altered energy homeostasis and myocardial inflammation, hypertrophy, and fibrosis. Adiponectin, an insulin-sensitizing adipocytokine, may affect these pathogenic factors, and the circulating adiponectin level may serve as a biological marker of CHF. This study aimed to assess the significance of serum adiponectin as a prognostic marker for Japanese CHF patients. Methods and ResultsThe serum adiponectin levels were compared between 54 (24 ischemic and 30 nonischemic) CHF patients with left ventricular systolic dysfunction and 55 age-and gender-matched control subjects. The CHF patients also underwent simultaneous clinical assessment and measurements for brain natriuretic peptide (BNP) and parameters of lipid or glucose metabolism. Com...

show abstract

Association of Hyperadiponectinemia With Severity of Ventricular Dysfunction in Congestive Heart Failure

Cited by 74 publications

References 42 publications

Relationship between adiponectin, obesity and insulin resistance

Relationship between adiponectin, obesity and insulin resistance

Adiponectin and Cardiovascular Disease

Serum Adiponectin Level as an Independent Predictor of Mortality in Patients With Congestive Heart Failure

Contact Info

Product

Resources

About